This prospective cohort followed 122 patients given lecanemab every two weeks at nine centres in Southwest China. Of these, 38.52% had mild cognitive impairment due to Alzheimer's disease (AD) and 40.98% had mild AD dementia. Treated patients had more favourable cognitive trajectories than propensity-matched local controls and an Alzheimer's Disease Neuroimaging Initiative natural-history cohort. At 13 months, 84.00% held or improved their Clinical Dementia Rating stage and 66.67% became amyloid-negative (Centiloid below 12). Amyloid reduction was not robustly linked to cognitive gain, and baseline clinical variables did not reliably predict response. Amyloid-related imaging abnormalities affected 10.66%, and the abstract does not say how many patients reached 13 months.
Why it is interesting: It adds 13-month real-world data on an anti-amyloid drug outside trial populations. Patients stopped mostly because repeated infusions were inconvenient, not because of safety concerns.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.